Agios Pharmaceuticals | Renteudgifter På Gæld



Interest Expense On Debt Lave om Dato
AbbVie USD 610M 19M 2024-12
Agios Pharmaceuticals 3.01M 10.05M 2024-12
Alnylam Pharmaceuticals USD 38.97M 4.6M 2024-12
Amgen USD 747M 29M 2024-12
Arrowhead Research USD 21.65M 7M 2024-12
Astellas Pharma 4.23B 821M 2024-12
AstraZeneca 429M 28M 2024-12
Bayer 703M 61M 2024-12
Biogen USD 60M 200K 2024-12
BioMarin Pharmaceutical USD 2.58M 391K 2024-12
Bristol-Myers Squibb USD 496M 9M 2024-12
Daiichi Sankyo 11.62B 11.42B 2024-09
Eli Lilly USD 224.7M 78.4M 2024-12
Exelixis 23.4M 3.9M 2023-09
Gilead Sciences USD 248M 10M 2024-12
GlaxoSmithKline 173M 17M 2024-12
Incyte USD 419K 355K 2024-12
Ionis Pharmaceuticals USD 2.59M 70K 2024-12
Merck USD 328M 2M 2024-12
Moderna USD 6M 0 2024-12
Novartis USD 275M 11M 2024-12
Novartis USD 275M 11M 2024-12
Pfizer USD 739M 45M 2024-12
Regeneron Pharmaceuticals USD 10.5M 3.3M 2024-12
Roche Holding CHF 311.5M 1000K 2024-12
Sarepta Therapeutics USD 4.92M 86K 2024-09
Vertex Pharmaceuticals USD 2.8M 4.7M 2024-12



Agios Pharmaceuticals Renteudgifter På Gæld - Aktuelle værdier, historiske data, prognoser, statistik, diagrammer og økonomisk kalender - Mar 2025.